- CHMP anbefalede derfor, at der for Avalox og tilknyttede navne (se bilag I) foretages ændring af
Characteristics sections 4.1, 4.2, 4.3, 4.4, 5.1 and 5.2 and Package Leaflet relevant sections as set out in Annex III for Avalox and associated names (see Annex I).